McArdle’s disease
Glycogen storage disease type V
مراجعة من قبل الدكتور كريشنا فاخاريا، MRCGPآخر تحديث بواسطة الدكتور كولين تايدي، MRCGPLast updated 18 مايو 2023
يتوافق مع الإرشادات التحريرية
- تنزيلتنزيل
- مشاركة
- Language
- نقاش
- نسخة صوتية
- Add to preferred sources on Google
المهنيين الطبيين
Professional Reference articles are designed for health professionals to use. They are written by UK doctors and based on research evidence, UK and European Guidelines. You may find one of our مقالاتنا الصحية more useful.
في هذه المقالة:
Synonyms: McArdle's syndrome, myophosphorylase deficiency, muscle glycogen phosphorylase deficiency, PYGM deficiency
McArdle's disease is caused by myophosphorylase deficiency (glycogen storage disease type V), first described by Brian McArdle in 1951. Most patients with McArdle's disease have undetectable myophosphorylase activity and are therefore unable to release glucose from glycogen in muscle.
See also the article on Glycogen Storage Disorders.
تابع القراءة أدناه
How common is McArdle’s disease? (Epidemiology)
A rare autosomal recessive disease, with heterozygotes being asymptomatic.
The gene for myophosphorylase (PYGM) is on chromosome 11.1 Mutations are spread throughout the gene and there is no clear genotype:phenotype correlation.2
It is now known as one of the most common disorders of muscle metabolism, with an estimated prevalence of approximately 1 per 100,000 people.3
In the UK approximately 1 person in 280,000 is diagnosed, and it is believed that many people remain undiagnosed.4
McArdle’s disease symptoms3
العودة إلى المحتوياتThe majority of patients with McArdle's disease first present in the first decade of life but are only diagnosed in the third or fourth decade of life. One review found that about 4% of cases are diagnosed before 10 years of age and about 50% are diagnosed between 10–30 years of age. The main symptoms are often tiredness, cramping and exercise intolerance.5
Presentation
Clinical presentation and severity are very variable but patients typically experience reversible exercise intolerance, fatigue and acute crises (severe fatigue and painful muscle cramps, sometimes with rhabdomyolysis and myoglobinuria) triggered by static muscle contractions (eg, lifting weights) or dynamic exercise (eg, climbing stairs or running).6
Following a period of careful pacing and/or rests (the initial pain usually subsides within less than one minute), after about 8 minutes most patients achieve a 'second wind' and can then continue exercise with less difficulty.
Symptoms tend to worsen with age as weight increases and aerobic fitness is reduced.
Fixed muscle weakness and wasting may occur, particularly in older patients.
Symptoms
Diagnosis is suggested by the history.
People with McArdle's disease develop severe muscle cramps and fatigue in the first few minutes of activity.
Individual presentation can be unique.
Some adults develop a progressive proximal weakness.
Some adults develop a fixed motor weakness.
The so-called 'second wind' phenomenon universal to all patients but some may not recognise it.
About one half of all patients will have experienced myoglobinuria (dark urine) following intense exercise.
علامات
Clinical findings may be absent on physical examination. Muscle strength and reflexes may be normal.
In later adult life, persistent proximal weakness and muscle wasting may be present.
تابع القراءة أدناه
التشخيص التفريقي
العودة إلى المحتوياتOther causes of الإرهاق المزمن.
التحقيقات
العودة إلى المحتوياتCreatine kinase levels are elevated in more than 90% of patients with McArdle's disease at rest.
A history of painful muscle cramps that occur within a few minutes of initiating activity and which subside rapidly with rest, in conjunction with a raised serum CK, is highly suggestive of McArdle's disease.7
Blood urate levels may be raised.
There is no increase in venous lactic acid levels following exercise testing.
Urine studies are indicated because myoglobinuria may occur after exercise.
In the UK, "hot spot" DNA testing for the two most common mutations can be arranged through the national McArdle Service. Up to 85% of patients can be confirmed without muscle biopsy.4
Electromyography: may show nonspecific myopathic changes or increased muscle irritability. Electrical activity may be absent during exercise-induced muscle cramps.
Diagnosis is by a muscle biopsy, which shows an excess of glycogen and absence of the muscle enzyme phosphorylase.4
DNA testing then provide genetic confirmation.4
تابع القراءة أدناه
McArdle's disease treatment and management
العودة إلى المحتوياتNo specific treatment exists. There is no evidence of significant benefit from any specific nutritional or pharmacological treatment in McArdle's disease.8
Anaesthetists should be made aware of the diagnosis of McArdle's disease, and may choose to avoid certain anaesthetic agents.4
Tourniquets should not be used during operative procedures in patients with McArdle's disease.4
Advice to patients:
It is important to avoid strenuous (anaerobic or sustained) activity, including lifting or pushing.4
Patients should not continue to exercise in the presence of pain, as this may increase the risk of rhabdomyolysis with myoglobinuria and subsequent acute kidney injury.6
However, regular aerobic exercise seems to be beneficial.8 It is important to take regular gentle exercise, such as walking or cycling. Keeping physically fit is the most effective way of controlling the symptoms of McArdle's disease and improving quality of life.
If an episode of myoglobinuria occurs, the patient should drink plenty of fluids.4
The patient should seek medical attention immediately if they feel unwell or stop producing urine.4
Excessive weight gain should be avoided, as increased weight lowers the aerobic threshold and increases the effort of exercise.4
Although there is some evidence of benefit with creatine, oral sucrose, ramipril and a carbohydrate-rich diet, there is no strong evidence to indicate significant clinical benefit.9
There are some reports that vitamin B6 may be beneficial.10
المضاعفات
العودة إلى المحتوياتSevere rhabdomyolysis may lead to acute kidney injury.1 Progression to مرض الكلى المزمن has not been described.
Seizures may occur but are extremely rare.
Potential hyperuricaemia; overproduction of adenosine monophosphate (AMP), with accelerated liberation of hypoxanthine and xanthine into the blood, possibly leading to hyperuricaemia.6
التكهن
العودة إلى المحتوياتMcArdle's disease is a chronic but often relatively benign disorder.
There does not seem to be any adverse effect on pregnancy and childbirth.4
Preventing McArdle's disease
العودة إلى المحتوياتGenetic counselling is appropriate for all individuals with a genetic disorder.
Exclusive updates for healthcare professionals
Stay informed with the latest clinical updates, professional insights, and evidence-based guidance. The Patient Pro newsletter curates essential content for healthcare professionals—delivered straight to your inbox.
By subscribing you accept our سياسة الخصوصية. يمكنك إلغاء الاشتراك في أي وقت. نحن لا نبيع بياناتك أبدًا.
قراءة إضافية ومراجع
- Glycogen Storage Disease V, GSD5; الوراثة المندلية البشرية عبر الإنترنت (OMIM)
- Vissing J, Duno M, Schwartz M, et al; Splice mutations preserve myophosphorylase activity that ameliorates the phenotype in McArdle disease. Brain. 2009 Jun;132(Pt 6):1545-52. doi: 10.1093/brain/awp065. Epub 2009 May 11.
- Kitaoka Y; McArdle Disease and Exercise Physiology. Biology (Basel). 2014 Feb 25;3(1):157-66. doi: 10.3390/biology3010157.
- Association for Glycogen Storage Disease UK
- Pomarino D, Martin S, Pomarino A, et al; McArdle's disease: A differential diagnosis of idiopathic toe walking. J Orthop. 2018 May 8;15(2):685-689. doi: 10.1016/j.jor.2018.05.024. eCollection 2018 Jun.
- Lucia A, Nogales-Gadea G, Perez M, et al; McArdle disease: what do neurologists need to know? Nat Clin Pract Neurol. 2008 Oct;4(10):568-77.
- Quinlivan R, Buckley J, James M, et al; McArdle disease: a clinical review. J Neurol Neurosurg Psychiatry. 2010 Nov;81(11):1182-8. doi: 10.1136/jnnp.2009.195040. Epub 2010 Sep 22.
- Quinlivan R, Vissing J, Hilton-Jones D, et al; Physical training for McArdle disease. Cochrane Database Syst Rev. 2011 Dec 7;(12):CD007931. doi: 10.1002/14651858.CD007931.pub2.
- Quinlivan R, Martinuzzi A, Schoser B; Pharmacological and nutritional treatment for McArdle disease (Glycogen Storage Disease type V). Cochrane Database Syst Rev. 2014 Nov 12;2014(11):CD003458. doi: 10.1002/14651858.CD003458.pub5.
- Izumi R, Suzuki N, Kato K, et al; A case of McArdle disease: efficacy of vitamin B6 on fatigability and impaired Intern Med. 2010;49(15):1623-5. Epub 2010 Aug 2.
تابع القراءة أدناه
About the authorView full bio

الدكتور كولين تايدي، MRCGP
General Practitioner, Medical Author
MBBS, MRCGP, MRCP (Paediatrics), DCH
Dr Colin Tidy is an NHS Doctor, based in Oxfordshire.
About the reviewerView full bio

الدكتور كريشنا فاخاريا، MRCGP
Chief Medical Officer for Health, Optum UK
MBChB, MRCGP(2013), BMedSci (hons), DFSRH, DRCOG, PGDipDerm (Distn)
Dr Krishna Vakharia is an NHS GP. She is also a regular examiner for the postgraduate Diploma in Practical Dermatology at Cardiff University as well as being the Chief Medical Officer for health at Optum UK.
تاريخ المقال
تمت كتابة المعلومات على هذه الصفحة ومراجعتها من قبل أطباء مؤهلين.
Next review due: 16 May 2028
18 مايو 2023 | أحدث إصدار

اسأل، شارك، تواصل.
تصفح المناقشات، اطرح الأسئلة، وشارك التجارب عبر مئات المواضيع الصحية.

هل تشعر بتوعك؟
قم بتقييم أعراضك عبر الإنترنت مجانًا